Talis Biomedical Statistics
Total Valuation
Talis Biomedical has a market cap or net worth of 3.10 million. The enterprise value is -37.97 million.
| Market Cap | 3.10M |
| Enterprise Value | -37.97M |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Talis Biomedical has 1.82 million shares outstanding. The number of shares has increased by 0.58% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.82M |
| Shares Change (YoY) | +0.58% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 8.32% |
| Owned by Institutions (%) | 0.01% |
| Float | 914,165 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.59 |
| PB Ratio | 0.06 |
| P/TBV Ratio | 0.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.74 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.94 |
Financial Position
The company has a current ratio of 7.76, with a Debt / Equity ratio of 0.39.
| Current Ratio | 7.76 |
| Quick Ratio | 7.30 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.47 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -70.48% and return on invested capital (ROIC) is -31.49%.
| Return on Equity (ROE) | -70.48% |
| Return on Assets (ROA) | -29.59% |
| Return on Capital (ROIC) | -31.49% |
| Revenue Per Employee | 4,121 |
| Profits Per Employee | -515,414 |
| Employee Count | 99 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.39% in the last 52 weeks. The beta is 1.57, so Talis Biomedical's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | -79.39% |
| 50-Day Moving Average | 1.75 |
| 200-Day Moving Average | 5.55 |
| Relative Strength Index (RSI) | 44.60 |
| Average Volume (20 Days) | 3,866 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.00 |
Income Statement
In the last 12 months, Talis Biomedical had revenue of 408,000 and -51.03 million in losses. Loss per share was -28.02.
| Revenue | 408,000 |
| Gross Profit | -20.09M |
| Operating Income | -46.35M |
| Pretax Income | -51.03M |
| Net Income | -51.03M |
| EBITDA | -45.58M |
| EBIT | -46.35M |
| Loss Per Share | -28.02 |
Balance Sheet
The company has 59.87 million in cash and 18.80 million in debt, giving a net cash position of 41.07 million or 22.53 per share.
| Cash & Cash Equivalents | 59.87M |
| Total Debt | 18.80M |
| Net Cash | 41.07M |
| Net Cash Per Share | 22.53 |
| Equity (Book Value) | 48.63M |
| Book Value Per Share | 26.68 |
| Working Capital | 55.41M |
Cash Flow
In the last 12 months, operating cash flow was -40.26 million and capital expenditures 23,000, giving a free cash flow of -40.24 million.
| Operating Cash Flow | -40.26M |
| Capital Expenditures | 23,000 |
| Free Cash Flow | -40.24M |
| FCF Per Share | -22.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | -11,360.29% |
| Pretax Margin | -12,506.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Talis Biomedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.58% |
| Shareholder Yield | -0.58% |
| Earnings Yield | -1,648.17% |
| FCF Yield | -1,298.41% |
Stock Splits
The last stock split was on July 6, 2023. It was a reverse split with a ratio of 0.0666667.
| Last Split Date | Jul 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0666667 |
Scores
Talis Biomedical has an Altman Z-Score of -11.66. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.66 |
| Piotroski F-Score | n/a |